Aurinia is a late clinical-stage biopharmaceutical company focused on developing and commercializing therapies to change the treatment paradigm for patients impacted by rare autoimmune and inflammatory conditions. Aurinia is advancing voclosporin as a potential best-in-class and first-in-class therapy for the treatment of lupus nephritis (LN) in the U.S. and EU. The company is also exploring voclosporin in other proteinuric kidney diseases, and is advancing voclosporin ophthalmic solution (VOS), a topical formulation, for the treatment of dry eye syndrome (DES). Aurinia is actively exploring opportunities to fully realize the untapped potential of novel therapies and create meaningful impact to meet patient needs.
Glenn Schulman, PharmD, MPH
Senior Vice President, Corporate Communications and Investor Relations
Aurinia Pharmaceuticals Inc.
#1203-4464 Markham Street
Victoria, BC V8Z 7X8